ProQR files 6-K, hosts AX-0810 safety/PK update, F-3 linked

Rhea-AI Filing Summary

ProQR Therapeutics N.V. filed a Form 6-K noting it hosted a virtual analyst and investor event titled “Entering the Clinic with AX-0810: Establishing Safety, PK, and the Biomarker Roadmap for Proof of Target Engagement.” The session covered its AX-0810 lead program, a strategic overview, and corporate outlook.

The related investor presentation is furnished as Exhibit 99.1. The company states that the information is incorporated by reference into its Form F-3 registration statements (File Nos. 333-282419, 333-270943, 333-263166, and 333-285767).

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-36622

PROQR THERAPEUTICS N.V.

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

On November 3, 2025, ProQR Therapeutics N.V. (“ProQR”) hosted a virtual analyst and investor event entitled “Entering the Clinic with AX-0810: Establishing Safety, PK, and the Biomarker Roadmap for Proof of Target Engagement” to discuss its AX-0810 lead pipeline program, along with a strategic overview and its corporate outlook. A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ProQR hereby incorporates by reference the information contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File No. 333-263166 and File No. 333-285767).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROQR THERAPEUTICS N.V.
Date: November 3, 2025	By:	/s/ Dennis Hom
		Dennis Hom
		Chief Financial Officer

INDEX TO EXHIBITS

Number		Description
99.1		Presentation of ProQR Therapeutics N.V. for November 3, 2025 Analyst and Investor Event.

FAQ

What did ProQR (PRQR) announce in this Form 6-K?

ProQR reported it hosted a virtual analyst and investor event focused on its AX-0810 lead program, strategy, and corporate outlook, and furnished the presentation as Exhibit 99.1.

When was ProQR’s AX-0810 investor event held?

The event took place on November 3, 2025.

What topics were discussed about AX-0810?

The event covered establishing safety, pharmacokinetics (PK), and the biomarker roadmap for proof of target engagement.

Where can I find the materials from the event?

The presentation is attached as Exhibit 99.1 to the Form 6-K.

Does this 6-K affect ProQR’s registration statements?

Yes. The information is incorporated by reference into ProQR’s Form F-3 registration statements (File Nos. 333-282419, 333-270943, 333-263166, 333-285767).

What is the primary focus of AX-0810 per the event title?

AX-0810 efforts focus on safety, PK, and a biomarker roadmap to demonstrate target engagement.